ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to Clinic

Author： Torphy T.J.   Barnette M.S.   Underwood D.C.   Griswold D.E.   Christensen S.B.   Murdoch R.D.   Nieman R.B.   Compton C.H.  

Publisher： Academic Press

ISSN： 1094-5539

Source： Pulmonary Pharmacology & Therapeutics, Vol.12, Iss.2, 1999-04, pp. : 131-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of PDE 4 Inhibitors, Rolipram and SB 207499 (ArifloTM, in a Rat Model of Pulmonary Neutrophilia

By Spond J.   Chapman R.   Fine J.   Jones H.   Kreutner W.   Kung T.T.   Minnicozzi M.  

Pulmonary Pharmacology & Therapeutics, Vol. 14, Iss. 2, 2001-03 ,pp. : 157-164

Academic Press

Access to resources Recommend Favorite

Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and COPD

By  

Current Medicinal Chemistry, Vol. 13, Iss. 27, 2006-11 ,pp. : 3253-3262

Bentham Science Publishers

Access to resources Recommend Favorite

Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease

By Giembycz Mark A  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 7, 2001-07 ,pp. : 1361-1379

Informa Healthcare

Access to resources Recommend Favorite

Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis

By Baumer W.   Gorr G.   Hoppmann J.   Ehinger A.M.   Ehinger B.   Kietzmann M.  

European Journal of Pharmacology, Vol. 446, Iss. 1, 2002-06 ,pp. : 195-200

Elsevier

Access to resources Recommend Favorite

Phosphodiesterase 4 inhibitors for the treatment of asthma

By Karlsson J-A.   Aldous D.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 9, 1997-09 ,pp. : 989-1003

Informa Healthcare

Access to resources Recommend Favorite